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Children with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) experience a higher 3 
prevalence of depression and anxiety compared to age-matched controls. Our previous systematic 4 
reviews in 2015/16 found little evidence for effective treatment for children with CFS/ME with 5 
comorbid depression and/or anxiety. This review updates these findings. 6 
Design 7 
A systematic review. We searched Cochrane library, Medline, Embase and PsychINFO databases 8 
from 2015-2020. We combined the updated results with our previous reviews in a narrative 9 
synthesis. 10 
Participants 11 
Inclusion criteria: <18 years old; diagnosed with CFS/ME (using Centre for Disease Control, National 12 
Institute for Health and Care Excellence, or Oxford criteria); validated measures of depression and/or 13 
anxiety. 14 
Interventions 15 
Observational studies or randomised controlled trials. 16 
Comparison 17 
Any or none. 18 
Outcomes 19 






The updated review identified two studies. This brings the total number of paediatric CFS/ME 1 
studies with a measure of anxiety and/or depression since 1991 to 16. None of the studies 2 
specifically targeted depression, nor anxiety. One new study showed the Lightning Process (in 3 
addition to specialist care) was more effective at reducing depressive and anxiety symptoms 4 
compared to specialist care alone. Previous studies evaluated cognitive behavioural therapy (CBT); 5 
pharmacological interventions; and behavioural approaches. CBT-type interventions had most 6 
evidence for improving comorbid anxiety and/or depressive symptoms but varied in delivery and 7 
modality. Other interventions showed promise but studies were small and have not been replicated. 8 
Conclusion  9 
Very few paediatric CFS/ME intervention studies have been conducted. This review update does not 10 
significantly add to what is known from previous reviews. The evidence is of poor quality and 11 
insufficient to conclude which interventions are effective at treating comorbid anxiety and/or 12 
depression in paediatric CFS/ME. 13 
Trial registration number  14 
Reviews are registered on the Prospective Register of Systematic Review Protocols: 15 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016043488 ; 16 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015016813. 17 
Key words 18 
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 20 
ARTICLE SUMMARY 21 





• This review used a systematic approach to identify updated evidence for treatment 1 
approaches for comorbid anxiety and/or depression in paediatric CFS/ME, and combined it 2 
with previous review results to provide a comprehensive synthesis of all evidence. 3 
• Non-English language articles were included. 4 
• Authors were contacted and sub-group data obtained when available. 5 
• Grey literature and unpublished material was not included. 6 
• There was insufficient data to carry out a meta-analysis. 7 
 8 
INTRODUCTION 9 
Chronic fatigue syndrome (CFS)/myalgic encephalomyelitis (ME) is a common but poorly understood 10 
condition causing disabling fatigue, malaise, myalgia, sleep difficulties, and problems 11 
concentrating[1]. In children and adolescents (henceforth referred to as children), prevalence is 12 
estimated at 0.55% (95%CI 0.22-1.35) across community, primary care and hospital populations[2]. 13 
CFS/ME has long-term impacts on children’s physical, cognitive, emotional and social functioning[3, 14 
4].  15 
 16 
Children with CFS/ME suffer from higher rates of both depression and anxiety than age-matched 17 
population samples. The prevalence estimates of comorbid depression and anxiety are 20%[5] and 18 
29%[6], respectively, compared to 2.1% and 7.2%[7] in adolescents without CFS/ME. In those 19 
attending a specialist CFS/ME service, 61% who meet diagnostic criteria for depression also have an 20 
anxiety disorder[5]. Having comorbid depression and/or anxiety is associated with less favourable 21 
outcomes and may impact on engaging with treatment. Comorbid depression in paediatric CFS/ME 22 
is associated with greater functional disability, worse fatigue and more pain compared with those 23 





engage in behavioural treatment approaches and Cognitive Behavioural Therapy-for-fatigue (CBT-f). 1 
Depressive symptoms are therefore likely to require tailored treatment[9]. The impact of anxiety on 2 
outcomes is less clear. Given that most children with CFS/ME who have anxiety also have 3 
depression[5], it is important to explore treatments for both. 4 
 5 
Despite the high prevalence of comorbid mental health problems, there is little evidence about the 6 
effectiveness of treatments. Our two previous systematic reviews looking at depression and anxiety 7 
outcomes in existing CFS/ME intervention studies found that no specifically adapted treatments had 8 
been trialled to target depression and anxiety in paediatric CFS/ME[10, 11]. Although CBT-f and a 9 
multicomponent inpatient programme showed promise in reducing depressive[10] and anxiety[11] 10 
symptoms, there was no consistent treatment approach for children with CFS/ME and comorbid 11 
depression or anxiety. Since conducting these reviews in 2015/16, further intervention studies may 12 
have been published. It is important and timely to review the current evidence to provide an update 13 
on what treatments should be offered to this population. Further, it is important to consider anxiety 14 
and depression together given their overlap, whereas our previous reviews considered them 15 
separately. 16 
 17 
We conducted an updated systematic review by synthesizing the evidence regarding treatments for 18 
paediatric CFS/ME and comorbid depression and anxiety since 2015. We combined these findings 19 
with results from our previous systematic reviews (1991-2015) to give an overview of all 20 
interventions evaluated since 1991 (when CFS/ME was scientifically defined). Specifically, we aimed 21 
to address the following: 22 





2. What is known about the treatment efficacy of these approaches for treating depression and 1 
anxiety in CFS/ME? Do different approaches have different outcomes? 2 
 3 
METHODS 4 
Data sources and search strategy 5 
We conducted searches on Medline, Embase, PsychINFO and Cochrane Library databases. We used 6 
the same search strategies from the previous systematic reviews (registered on Prospero:  7 
CRD42015016813; CRD42016043488) to repeat the depression and anxiety searches separately. 8 
Searches were designed with input from an information specialist to include the concepts: 9 
paediatric; CFS/ME; anxiety and depression (search strategies are in supplementary material). We 10 
updated the searches from when they had last been run (February 2015 for depression search and 11 
July 2016 for anxiety search) up until September 2020. The two searches were carried out by 12 
different reviewer teams: anxiety search (PC, AR); depression search (KD, JB). Grey literature was not 13 
searched. Reference lists of articles for full-text screening were hand-searched.  14 
 15 
Inclusion and exclusion Criteria 16 
Studies were included if they met inclusion criteria (Table 1).  17 
Table 1: Inclusion criteria 
 
 Anxiety Review Depression Review 
Participants 
1. Children <18 years of age 
 
2. Diagnosed with CFS/ME defined using one of these criteria: 
CDC aka Fukuda[12] 
NICE[1] 






Observational cohort studies 
Any study with intervention – e.g., observational clinical cohorts, clinical 
trials, etc. 
Baseline measure Validated assessment of anxiety Validated assessment of depression 
Outcome measure 
Either an anxiety and/or fatigue 
measure on psychometrically 
validated assessments or 
validated diagnostic interviews. 
Either a depression and/or fatigue 
measure on psychometrically 
validated assessments or validated 
diagnostic interviews. 
Language Non-English language papers were considered for inclusion. 
 1 
Study selection 2 
Articles returned from database searches were inputted into Endnote and duplicates removed. Each 3 
reviewer conducted title and abstract screening independently. Full texts of potentially eligible 4 
articles were screened against specifically created eligibility checklists. The final articles for inclusion 5 
were cross-checked between all four reviewers and any conflicts discussed and resolved with input 6 
from the senior author (ML) if necessary. Where information from the paper was insufficient to 7 
determine eligibility, authors were contacted by email for additional information. If authors did not 8 
reply after two follow-up emails, the study was excluded. Figure 1 presents the PRISMA[14] 9 
flowchart. 10 
 11 
Data extraction 12 
For all included articles, data were extracted independently by two reviewers (PC, AR) using a 13 
purpose-designed data extraction form to collect information about: study design; setting; 14 
recruitment; participant characteristics; CFS/ME definition used for diagnosis; assessment of 15 
depression and anxiety; other outcomes; treatment and interventions provided; definition of 16 






Quality assessment 2 
PC and AR used Risk of Bias assessment tools[15, 16] to assess methodological quality of the 3 
included studies. 4 
 5 
Data synthesis 6 
We combined results from the included studies identified in the updated search with findings from 7 
the two previous systematic reviews[10, 11] to conduct a narrative synthesis[17], providing an 8 
overview of all longitudinal studies that have been evaluated in this clinical cohort since 1991 (when 9 
CFS/ME was scientifically defined). There was insufficient comparable data to conduct a meta-10 
analysis as interventions were heterogeneous and a range of outcome measures were reported. For 11 
each of the new studies, the effects of interventions on outcomes using mean differences were 12 
compared. 13 
 14 
Patient and public involvement 15 
No patients were involved. 16 
 17 
Ethics approval 18 
This study did not involve human participants. 19 
 20 
RESULTS 21 





In the updated search (2015-2020), a total of 625 and 415 references were found by database 1 
searching for the depression and anxiety searches, respectively. After full-text screening, both 2 
searches returned the same two eligible studies[18, 19]. One was an RCT[19], one was a 3 
retrospective observational cohort study[18]. The PRISMA[14] flowchart is in Figure 1. 4 
[Figure 1 here] 5 
 6 
The previous systematic reviews for depression[10] (search conducted in 2015) and anxiety[11] 7 
(search conducted in 2016) found 362 and 1274 references, respectively. After full-text screening, 8 
the depression search returned nine eligible studies (one RCT[20], and eight observational[21-28]), 9 
and the anxiety search returned nine eligible papers from eight studies (three RCTs[29-32], six 10 
observational studies[21, 23, 24, 27, 33, 34]). Four of the studies from these two searches were the 11 
same.   12 
Therefore, in total, 16 eligible studies were included in the narrative synthesis review. Figure 2 13 
shows a flowchart combining studies from this updated search with studies identified from previous 14 
reviews. 15 
[Figure 2 here] 16 
 17 
Quality assessment 18 
Of the total 16 studies in this review, ten were observational and six were RCTs. Of the observational 19 
studies, five had an overall risk of bias as “unclear”, and five had “high” risk of bias (as defined by the 20 
Cochrane risk of bias scale, ROBINS-I[15]). Of the RCTs, all six had an overall rating of “low” risk of 21 
bias (as defined by the Cochrane risk of bias scale (ROB-2[16]). See supplementary material for the 22 





previous searches, please refer to our previous two reviews[10, 11]. In this paper we report in detail 1 
on the quality assessment of the two new studies found in the updated search. 2 
 3 
The RCT[19] was conducted by members of our CFS/ME research team (EC). The study has a low risk 4 
of bias from the concealed allocation randomisation process, minimal deviation from how 5 
interventions were intended to be delivered, and appropriate intention-to-treat analysis. Outcome 6 
measurement is biased because of self-reported measures, but this is standard for behavioural 7 
treatments. It is also biased due to loss to follow-up. In the control arm at 3 months, 13 of 49 (27%) 8 
were lost to follow-up and at the primary outcome of 6 months, 12 of 49 (24%) were not included in 9 
analysis. In the intervention arm 8 of 51 (16%) were lost to follow-up at 3 months and 7 of 51 (14%) 10 
were not included in primary analysis at 6 months. Although baseline characteristics between those 11 
who did and did not provide primary outcome data were similar, it is possible that missingness was 12 
related to the outcome. 13 
 14 
The retrospective observational study[18] is also biased due to poor follow-up rates at any one time 15 
point (making comparison difficult), and no pre-published analysis plan. In the cohort, there are two 16 
samples; one with baseline data for anxiety and depression and one without. Follow-up 17 
questionnaires were mailed to all participants on a number of occasions between January 2008 and 18 
June 2011. This produced a range of follow-up time points (1-21 years) after illness onset, meaning 19 
some patients would not have had contact with the clinic for a long time when they were sent the 20 
questionnaire, so it is likely that both disease status and time since illness influenced outcome data.  21 
Of the 489 patients who were sent baseline questionnaires, 74% returned a follow-up questionnaire 22 
on at least one occasion (range one to seven). For the sample of 366 without baseline data for 23 





returned a questionnaire on more than one occasion. Outcome measures were also self-reported, 1 
and many participants did not complete all measures. 2 
 3 
Participant and study characteristics  4 
The two studies identified in the updated search were: an RCT evaluating the ‘Lightning Process’ 5 
intervention alongside ‘specialist medical care’ compared with ‘specialist medical care’ alone[19]; 6 
and an observational cohort study assessing ‘routine specialist care’ over a 20-year period[18]. 7 
Studies from the previous reviews included the following. Four RCTs evaluating: inpatient 8 
programmes with predominantly behavioural approaches[20, 30], an online CBT programme[31, 32], 9 
and intravenous gammaglobulin[29]; eight observational cohort studies evaluating: CBT[21, 27, 34], 10 
CBT with pharmacotherapy[26, 33], an anti-viral treatment[28], and an inpatient programme[25]; 11 
and two prospective observational community studies that did not assess a specified 12 
intervention[23, 24]. Follow-up times varied from immediately post-treatment to 21 years. Total 13 
number of participants included across all studies was 965. Most sample sizes were small but ranged 14 
between one and 418. Participant ages ranged between 11 and 18. Most studies were conducted 15 
across Europe (UK, Netherlands, Spain) and Australia. One was in Japan, one in the USA (Table 2). 16 
 17 
None of the studies identified were specifically aimed at treating anxiety or depression in children 18 
with CFS/ME (all primary outcomes were measures of fatigue or recovery). Anxiety and/or 19 
depression were measured as secondary outcomes using a variety of self-report questionnaires 20 
including the Hospital Anxiety and Depression Scale (HADS)[35], Spence Children’s Anxiety Scale 21 
(SCAS)[36], the State-Trait Anxiety Inventory for Children (STAIC)[37], the Multidimensional Anxiety 22 
Scale for Children (MASC)[38], Spielberger State Trait Anxiety Questionnaire (SSTAQ)[39], Beck 23 





Scale[42], and Zung’s Self-rating depression scale[43]. One study used a diagnostic interview, the 1 
Development and Well-Being Assessment (DAWBA)[44]. Six studies (including the two identified in 2 
the updated review) measured both anxiety and depression; five measured depression only; and five 3 






































(a) Studies Identified in Updated Review                             








N/A 418 (789 
recruited but 
366 did not 
have baseline 
questionnaire) 




STAI, BDI No No Routine specialist medical care 
provided in the outpatient clinic. 
Described as a person-centred 
goal-oriented holistic program 
which targets educational, 
physical, social and emotional 
aspects of life.  
N/A Mean: 
8 years; 
Range 1- 21 
years 
Crawley et al 
(2018)[19], 
UK 
Both RCT Outpatient 
secondary 
care 
49 51 14.5 14.7 78% 75% NICE  SF-36 PFS at 6 
months 
SCAS, HADS No No Specialist medical care (Based on 
NICE guidance) + Lightning 
Process® (3 x 4-hour sessions on 
consecutive days with groups of 
2-5 young people. Theory 
sessions teach the stress 
response, how the mind and 
body interact and how thought 
processes can be either helpful or 
negative. Practical sessions 
involve participants identifying a 
goal (e.g. stand up for longer) and 
are given cognitive strategies.)  
Specialist medical 
care only 
3, 6, 12 
months  











N/A 15 (14 at follow-
up) 
N/A 15.46 N/A 73% CDC/Fukuda Fatigue self-
assessment 
scores (CFSI, 
FSS, FSI, MFSI) 
CDI No Yes Valacyclovir (antiviral) 
medication, initially 500mg BID, 
increasing after 2-3 weeks. 
Duration of treatment ranged 














49 (24 at follow-
up) 





SCAS No No CBT via telephone based guided 
self-help. 6 fortnightly sessions, 
30mins duration 
N/A 6 months 




Anxiety Both RCTs Outpatient 
secondary 
care 
67 (63 at 
follow-up) 
68 (64 at follow-
up) 







STAIC  No No Internet delivered CBT consisting 
of psychoeducation and 21 
modules, with parallel child and 
parent sessions. FITNET therapist 
individually tailored intervention 
and initially responded to emails 
weekly, decreasing to fortnightly. 
Mean treatment duration 26.2 

















Lloyd et al 
(2012)[27], 
UK 
Both Observational Outpatient 
secondary 
care 
N/A 63 (52 at follow-
up) 













No No CBT via telephone based guided 
self-help. 6 fortnightly sessions, 
30mins duration 




Depression Observational Outpatient 
secondary 
care 








No No CBT (average of 5 sessions over 6 


























BDI No No 4 week inpatient programme including graded exercise 
therapy, psychological/psychiatric support, attendance 
at school. 
 
Patients randomised to either graded aerobic exercise 
training or progressive resistance training programme 
for 5 days/week for 4 weeks. The graded aerobic 
training consisted of 20-40 minutes of stationary 
cycling and treadmill exercise. The progressive 
resistance training involved 16 exercises performed 







Depression Observational Inpatient 
secondary 
care 









score of SF-36 
BDI No No 4 week inpatient programme 
including graded exercise 
therapy, 
psychological/psychiatric 
support, attendance at school, 

















MASC No No CBT + fluoxetine (initially 10mg 
daily, increased after 1 week to 
20 mg) 






Community N/A 1 case of CFS at 
time 1; 4 cases 
of CFS at time 2 






DAWBA No No None specifically stated or 
evaluated 
N/A 4-6 months 






Community N/A 40 at baseline, 
36 at follow-up 
N/A 16 N/A 78% CDC/Fukuda Fatigue  SSTAQ, CDI No No None specifically stated or 
evaluated  





Wright et al 
(2005)[30], 
UK 
Anxiety RCT Outpatient 
secondary 
care 
6 (5 at 
follow-up) 
7 (6 at follow-
up) 






HADS No No STAIRway to Health intervention 
is a structured rehabilitation 
programme including 
conceptualising CFS as having 
both physical and psychological 
components, formulating and 
addressing vicious cycles around 
activity, sleep, social isolation, 
physical deconditioning, and 
developing adaptive coping 
strategies whilst challenging 
negative and unhelpful 
attributions about illness and the 
future. 
Pacing - focuses 
on limiting 
activity to the 
changing needs 
and responses of 











Depression Observational Inpatient 
secondary 
care 
N/A 39 (19 at follow-
up) 







BDI No No 4 week inpatient programme, 
focused on graded exercise using 
hydrotherapy and physiotherapy. 
N/A 6 months 
Chalder et al 
(2002)[21], 
UK 
Both Observational Outpatient 
secondary 
care 






HADS No No CBT based rehabiliation 
programme. Up to 15 sessions, 1 
hour duration. 
N/A 6 months 
Rowe et al 
(1997)[29], 
Australia 
Anxiety RCT Outpatient 
secondary 
care 














3 and 6 
months 
Note: CDC classification criteria for CFS/ME, also known as Fukuda criteria; Oxford criteria, also known as Sharpe et al criteria; SCAS, Spence Children's Anxiety Scale; HADS, Hospital Anxiety and Depression Scale; STAI(C), State-Trait Anxiety Inventory (for children); BDI, Beck’s Depression Inventory; CDI, Children’s Depression Inventory; MASC,  
Multidimensional Anxiety Scale for Children; DAWBA,  Development and Well-Being Assessment; SSTAQ, Spielberger State-Trait Anxiety Questionnaire; SF-36 PFS, Short-form-36 physical function subscale; CFSI, Chronic Fatigue Syndrome Symptom Inventory; FSS, Fatigue Severity Scale; FSI, Fatigue Symptom Inventory; MFSI, Multidimensional 
Fatigue Symptom Inventory-Short Form; Global rating was measured on multiple scales of functioning (incl. school/work, stamina, recovery, social and symptomatology) from 1-10, with 10 being "back to normal"; † qualitative feedback included: what was useful/helpful in treatment, their perceived effectiveness, and whether anything could have 







Treatment approaches and their efficacy treating anxiety and/or depression in paediatric CFS/ME 1 
Of the 16 studies: one study evaluated routine specialist outpatient care[18]; one evaluated the 2 
Lightening Process outpatient intervention[19]; one evaluated the ‘STAIRway to health’ outpatient 3 
intervention[30]; six evaluated various outpatient CBT programmes[21, 26, 27, 31-34]; two 4 
evaluated outpatient pharmacological interventions (antivirals[28] and gammaglobulins[29]); three 5 
evaluated inpatient programmes focussed on graded exercise therapy[20, 22, 25]; and two were 6 
epidemiological observational studies so were uninformative about interventions[23, 24]. 7 
 8 
There were common cognitive and behavioural elements across the behavioural and CBT 9 
programmes, including: behavioural strategies for a goal-oriented graded approach to increasing 10 
activity, often with the goal to return to full-time education or to commit to a regular activity; 11 
cognitive strategies to address the psychological implications of CFS/ME, illness-related beliefs and 12 
negative thoughts; and psychoeducation about the consequence of the illness and tools to navigate 13 
this. They varied in their intensity (e.g. inpatient treatment, consecutive daily four-hour outpatient 14 
sessions, and fortnightly 30-minute phone calls), duration of treatment (days to years), and modality 15 
(e.g. face-to-face, telephone, and online). The antiviral and gammaglobuin studies did not include 16 
these elements and were distinct from the other studies in their approach. 17 
 18 
Table 3 summarises outcomes of depression and/or anxiety and other relevant findings for each 19 
included study from (a) the updated review, and (b) previous reviews. Below, we discuss the efficacy 20 
of the treatment approaches in the 14 studies which evaluated an intervention, by whether they 21 





Table 3: Summary of outcomes for symptoms of depression and anxiety and other relevant findings for included studies 
Study  Measure of 
Depression 
and Anxiety 
Pre treatment: depression, 
mean(SD) 
Pre treatment: anxiety, 
mean(SD) 
Post treatment: depression, 
mean(SD) 
Post treatment: anxiety, mean(SD) Statistical analysis of change in depression/anxiety 
symptomatology 
Summary of other relevant findings 






Control Depression Anxiety 
(a) Studies Identified in Updated Review 








13.8 (8.9) N/A 88.9 (24.9) N/A N/A N/A N/A N/A No statistical change because post-treatment scores were not 
measured. Instead, mean baseline depression and anxiety 
scores were compared between those who reported 
recovery‡ and those who did not, using the student's t-test. 
Overall, 46.5% reported recovery; 
participants who were followed for >10 
years, 68% reported recovery 
 
Mean duration of illness was 5 years  






















12 months: 2.8 
6 months: 5.9 
 
12 months: 4.6 
HADS 
6 months: 6.1 




6 months: 24.7 
12 months: 19.6 
HADS 
6 months: 9.7 




6 months: 37.4 
12 months: 36.3 
Adjusted difference in 
means† (95%CI, pvalue): 
 
6 months: 
-1.5 (-3.5 to 0.5, p=0.1) 
 
12 months: 
-1.8 (-3.4 to -0.1, p=0.04) 




HADS at 6 months: 
-3.5 (-5.6 to -1.5, p=0.001) 
 
SCAS at 6 months: 
-10.0 (-18.5 to -1.5, p=0.02) 
 
HADS at 12 months: 
-2.6 (-4.7 to -0.4, p=0.019); 
 
SCAS at 12 months: 
14.5 (-22.4 to -6.7, p<0.001) 
At 6 months, participants allocated to 
LP in addition to SMC (intervention) 
had better physical function and 
fatigue at than those allocated to SMC 
(control). 
 
At 12 months, participants allocated to 
LP in addition to SMC (intervention) 
had better fatigue and school 
attendance than those in SMC 
(control). 
 
Adding LP to SMC is cost-effective. 
(b) Studies Identified in Previous Reviews 
Henderson 
(2014)[28]  
CDI 14 (2.83) 
 




11 patients without 
mood disorder: 
12.73 (2.00) 
N/A N/A N/A Not reported N/A N/A N/A Not reported N/A All patients reported at least 80% self-
rated improvement. Significant 





Rimes et al 
(2014)[34] 











N/A N/A Not reported N/A N/A T value (21)= 2.1.  
p=0.005 
Adolescents with CFS had reduced 
cortisol excretion throughout the day 
compared to healthy controls.  
There was significant improvement in 
school attendance after treatment 
from 24% to 49%.  
There was reduction in fatigue after 
treatment, however the results were 
not significant. 
Nijhof et al 
(2012[31], 
2013[32]) 
STAIC N/A N/A 32.7 (8.8) 32.3 (8.0) N/A N/A Not reported N/A N/A Not reported Intervention (FITNET) was significantly 
more effective than the control (usual 
care) at 6 months—full school 
attendance (50 [75%] vs 10 [16%], 
relative risk 4·8, 95% CI 2·7–8·9; 
p<0·0001), absence of severe fatigue 
(57 [85%] vs 17 [27%], 3·2, 2·1–4·9; 
p<0·0001), and normal physical 
functioning (52 [78%] vs 13 [20%], 3·8, 
2·3–6·3; p<0·0001). The short-term 
effectiveness of FITNET was maintained 
at 2.5 years follow-up. At 2.5 years 
follow-up, usual care led to similar 
recovery rates, although progress had 
taken longer to make. 
 
 At 6 months additional analyses of 
main findings with adjustments for 
anxiety, depression, and primary 
outcomes, had no effects on the 
results. 
 
When looking at factors related to 
recovery at 2.5 years, anxiety OR 1.01 
(95% CI 0.96-1.06), P = 0.66 









mean 12.91 (5.57) 
N/A Baseline 
mean 22.84 







N/A Post-treatment:  
10.98 (5.35) 
 
3 months: 10.47 ( 
5.87) 
 
6 months: 9.22 
(5.36) 
N/A 6 months: 
17.25 (3.06) 
N/A Multi-level modelling and 
Wald tests 
Treatment effect estimate 
at 6 months: 3.69 (CI -5.17, 
-2.21), significance (two-
tailed) <0.001, effect size 
0.78. 
Multi-level modelling and Wald 
tests 
Treatment effect estimate at 6 
months: 0.49, significance 
(two-tailed) 0.003, effect size 
0.16 
Significant improvement in fatigue and 
school attendance, with reductions in 
depression and impairment and 
increased adjustment at 6 months 
 






53.3 (6.7) N/A N/A N/A Not reported N/A N/A N/A Not reported N/A No significant change between baseline 
fatigue scores and fatigue scores 6 
months follow-up. Significant 
improvement in performance status 



















N/A N/A Resistance arm 




Difference -4.2 +/- 4.8 
p= 0.002 
N/A There was no control group. Significant 






BDI 19.88 (8.62) N/A N/A N/A 11.44 (10.98) N/A N/A N/A Paired t test p value 0.001, 
sig 0.008 
N/A Significant improvement in Fatigue 
Severity scores. 
Diaz Caneja et 
al (2007)[33] 








N/A N/A N/A Not stated 




N/A N/A Not reported Report of a moderate response to 
treatment with the young person 
tolerating more activity. She had 
resumed contact with her friends, and 
although she still complained of 




DAWBA Only states "3 of 4 




N/A Only states "3 





N/A N/A N/A N/A N/A Not reported Not reported Of the 4 participants who developed 
CFS/ME over the follow-up period, 3 of 
4 had at least 1 psychiatric diagnosis at 
baseline, 3 had reported being ‘much 
more tired and worn out than usual 
over the last month’ at time 1, 2 
participants had frequent headaches at 
time 1, 1 also had sleep problems and 
post-exertional malaise at time 1. 






11.7(6.1) N/A 36.9 (7.8) N/A Not stated N/A Not stated N/A Not reported Not reported 47% of adolescents ‘fully recovered’ 
(below score that is mean plus 2 SD of 
subjective fatigue distribution in health 
adolescents). 








N/A Analysis of covariance for 
anxiety, controlling for baseline 
score. Difference -1.60 (-8.31-
5.10) 
F 0.3 (df 1,8) 
p=0.6 
Activity (child and clinician rated) and 
school attendance improved markedly 
in the intervention (STAIRway) arm 
compared to little improvement in 
activity scores in the control (Pacing) 
arm, and a deterioration in school 
attendance. Global health (child and 
clinician rated) improved in both arms 
although more in the STAIRway arm 







BDI 21 N/A N/A N/A 15 N/A N/A N/A Improvement p<0.001 
Maintained at 6 month 
follow-up (p<0.038) 
N/A On discharge, mean depression score 
significantly better than on admission. 
Also significant improvement in Chronic 
Fatigue Illness Disability score and 
significant decrease in FSS score 
(maintained at 6 months follow-up). 
Achenbach/Youth Self-Report scores 
improved significantly by discharge, but 
returned to above admission levels at 6 
months. 
Chalder et al 
(2002)[21] 
HADS 8.4 (interquartile 
range 5.7-11) 
N/A HADS anxiety: 




N/A 6 months: 
3 (interquartile 
range 3-5) 
N/A 6 months:  
HADS anxiety: 
0.5 (IQ range 
0.5-9) 
N/A Wilcoxon signed ranks test -




Wilcoxon signed ranks test 
(significance 2 tailed) 
HADS anxiety: 2.02 (0.04) 
 
Depression: The 20 participants who 
completed treatment had all returned 
to school at 6 months follow-up, with 
19 of 20 attending full time. Depression 
significantly improved, as did social 
adjustment.  
 
Anxiety: All 20 treatment completers 
returned to school at 6 months follow-
up, with 95% attending full time. 
Depression significantly improved, as 
did social adjustment. 
Rowe et al 
(1997)[29] 
SSTAQ N/A N/A Reported as 1 group: 
Mean 46.2 (24.4) 
SE 3.9 
Range 0-98 
N/A N/A 6 months: 
Mean 28.1 (25.0) 
SE 5.9 
Range 0-77 
N/A T value (df) 2.63 (56) 
Sig p value 0.01 
Significant mean functional 
improvement in both groups. 
Note: *higher score=more symptoms, poorer function; † adjusted for age, gender, baseline outcome, SCAS and visual analogue scale; ‡reported recovery was based on the question "Do you feel you are no longer suffering from CFS?” (yes/no).  
 
HADS, Hospital Anxiety and Depression Scale (score >8 indicates a diagnosis of depression); SCAS, Spence Children’s Anxiety Scale ; BDI, Beck’s Depression Inventory (score >20 indicates moderate depression); STAI(C), State-Trait Anxiety Inventory (for children); BDI, Beck’s Depression Inventory; CDI, Children’s Depression Inventory; MASC,  
Multidimensional Anxiety Scale for Children; DAWBA, Development and Well-Being Assessment; SSTAQ, Spielberger State-Trait Anxiety Questionnaire; SF-36 PFS, Short-form-36 physical function subscale; CFSI, Chronic Fatigue Syndrome Symptom Inventory; FSS, Fatigue Severity Scale; FSI, Fatigue Symptom Inventory; MFSI, 





1. Outpatient programmes 1 
The two new studies from this updated review evaluated two outpatient programmes. Crawley et 2 
al[19] compared adding the Lightening Process intervention (https://lightningprocess.com) to 3 
specialist care (recommended by NICE[1]), to specialist medical care alone. The Lightening Process is 4 
developed from osteopathy, life coaching and neurolinguistic programming and more than 250 5 
children use it for their CFS/ME each year in the UK[46]. It is delivered in intensive three, four-hour 6 
sessions on consecutive days in small groups, with theory elements on the stress response, how the 7 
mind and body interact and how thought processes and language can be either helpful or negative, 8 
followed by practical sessions where participants identify an activity goal and are given cognitive 9 
strategies to attempt it. The study showed a significant reduction in adjusted difference in mean 10 
depressive and anxiety symptoms at 12 months (-1.8, p=0.04 for depression; -14.5, p<0.001 for 11 
anxiety) among participants allocated to the Lightening Process intervention (in addition to specialist 12 
medical care) arm than those allocated to the specialist medical care-only control. The Lightening 13 
Process was more effective than specialist medical care at reducing anxiety symptoms compared 14 
with depression (at both 6 and 12 months follow-up). Outcomes in this study were not stratified by 15 
those with depression or anxiety, so we cannot comment on other CFS/ME outcomes (such as 16 
fatigue or recovery) in context of comorbid depression or anxiety. 17 
 18 
The other study identified in this updated review evaluated routine specialist care delivered at the 19 
authors’ CFS/ME outpatient clinic in Australia[18]. Routine specialist care offers a “person-centered 20 
goal-oriented holistic programme” to “target educational, physical, social and emotional aspects of 21 
life”. This includes symptom management (e.g. sleep, migraine, dizziness, nausea, orthostatic 22 
intolerance, concentration difficulties) and focussing on increasing activity and a commitment to 23 
something enjoyable outside the home on a regular basis. This study measured depressive and 24 





of the intervention at reducing depression or anxiety. Instead, the study compared mean baseline 1 
depression and anxiety scores between those who had self-reported ‘recovery’, defined as 2 
answering “yes” to the question “Do you feel you are no longer suffering from CFS?” measured at a 3 
mean length of follow-up of 8 years (range 1-21). There was no difference in depression or anxiety at 4 
baseline between those who reported that they had recovered and those who had not i.e. 5 
depression nor anxiety were found to be associated with recovery.  6 
  7 
As per our previous reviews[10,11], several studies have evaluated other outpatient programmes. 8 
Outpatient CBT interventions demonstrated inconsistent efficacy and varied in terms of delivery 9 
modality (family-focused; face-to-face; telephone; or internet-delivered modules with therapist e-10 
consults), intensity (15 weekly, hourly therapist-led sessions; six fortnightly 30-minute telephone 11 
calls), duration of treatment (12 weeks to one year), and whether pharmacotherapy was offered 12 
alongside CBT (anti-depressants and anti-hypotensives). Three observational studies showed that 13 
face-to-face and telephone CBT resulted in improved depression, anxiety, functioning and social 14 
adjustment[21, 27, 34]. An RCT showed that participants who received internet-based CBT 15 
demonstrated improvement in fatigue and school attendance at 6-months follow up, compared to 16 
participants who received usual care[32]. However, the study did not measure anxiety at follow-up. 17 
Two studies that evaluated CBT alongside pharmacotherapy were uninformative as they either did 18 
not reassess mood at follow-up[26], or reported on only a single case-study[33]. In terms of 19 
behavioural approaches, the STAIRway to Health – an incremental rehabilitation intervention – 20 
showed greater improvement in anxiety levels, when compared with a ‘pacing’ intervention in an 21 
RCT[30].  Pharmacological studies showed insufficient evidence for improving anxiety or depressive 22 
symptoms with intravenous gammaglobulin infusions or vancyclovir respectively[28, 29] 23 
 24 





As per our previous review[10], three studies[20, 22, 25] including one RCT, evidenced an 1 
improvement in mood post-treatment with a 4-week inpatient behavioural programme focused on 2 
graded exercise (including physiotherapy, aerobic exercise and resistance training), which were 3 
maintained at 6-month follow-up in one study[22]). However: they did not measure anxiety 4 
symptoms; internalising problems at 6-months returned to pre-admission levels; two studies did not 5 
have follow-up data[20, 25]; all studies had small sample sizes; and the multicomponent 6 
intervention also included psychological therapy (with no further specified details about this). 7 
Therefore, these studies are uninformative for drawing conclusions about the efficacy of this 8 




Our updated review of interventions for comorbid depression and/or anxiety in children with 13 
CFS/ME identified only two new studies published since 2015 (one of which was conducted by 14 
members of our own research team) exposing the lack of progress in this field. One study (an RCT) 15 
showed that adding the Lightening Process intervention to specialist medical care was more 16 
effective than specialist medical care alone at reducing both depressive and, to a greater extent, 17 
anxiety symptoms. The other study (an observational cohort evaluating routine specialist care) did 18 
not measure depression or anxiety at follow-up. Combined with our results from previous reviews, 19 
we identified 16 studies of 11 different interventions for paediatric CFS/ME since 1991 that include 20 
measures of anxiety and/or depression. Of these, six did not provide follow-up measurements of 21 
anxiety and/or depression post-intervention, and none of the interventions in the studies specifically 22 
targeted comorbid anxiety and/or depression. The results of this updated review do not appreciably 23 





what the best interventions are for treating anxiety and/or depression in paediatric CFS/ME 1 
patients. 2 
 3 
Strengths of the updated review include the systematic approach, the use of four reviewers, 4 
contacting authors for sub-group data, and not limiting results to English language. The limitations 5 
are the lack of eligible studies and insufficient data available for a meta-analysis. Only two papers 6 
were eligible for inclusion, of which one did not provide sufficient follow-up data to comment on the 7 
treatment efficacy of the intervention on depression and anxiety. Neither intervention was 8 
specifically designed to measure the impact on depression and anxiety and therefore studies were 9 
inadequately powered to measure this. Studies were not stratified by those who met criteria for 10 
clinical diagnoses of depression/anxiety reducing our ability to analyse effectiveness. Furthermore, 11 
neither study used diagnostic interviews for anxiety and depression, relying instead on 12 
questionnaires. Whilst HADS[47], SCAS[48], and STAI[37] questionnaires are validated for use in 13 
adolescents, only the RCADS (Revised Children’s Anxiety and Depression scale), which is derived 14 
from the SCAS, has been found to have sufficient discriminative accuracy against gold standard 15 
diagnostic interviews in paediatric CFS/ME populations[5].  16 
 17 
In conjunction with our previous reviews, we show that currently the interventions with most 18 
evidence for improvement in anxiety and depressive symptoms in CFS/ME, when compared to other 19 
interventions, such as behavioural-only or pharmacological, is CBT[10, 11]. The 'Lightening Process' 20 
programme, ‘STAIRway to Health’ intervention, and a 4-week multicomponent inpatient 21 
rehabilitation programme show promising results for improving anxiety and/or depressive 22 
symptoms in single RCTs, but sample sizes are small and results have not been replicated.  The 23 
mechanisms for why CBT could be effective are unclear because no study targeted anxiety and 24 





identify the effective element of interventions. Our updated review does not further this debate 1 
because, whilst CBT is an element of ‘specialist medical care’ and ‘routine specialist care’ 2 
interventions in the new studies, we do not know how many participants received CBT or how it was 3 
delivered. Additionally, results are not stratified by those with anxiety and/or depression. 4 
Furthermore, the differences and similarities between the Lightening Process and CBT are also 5 
unclear[49]. It should also be noted that the draft NICE guideline (expected publication date August 6 
2021: https://www.nice.org.uk/guidance/gid-ng10091/documents/draft-guideline) does not 7 
recommend the Lightning Process for management of CFS (although this is not specifically aimed at 8 
anxiety and depression). 9 
 10 
Other cognitive and behavioural based approaches are being trialled in CFS/ME, but are limited in 11 
contributing to our understanding of their efficacy for anxiety and depressive symptoms in CFS/ME 12 
because of a failure to include paediatric CFS/ME populations or those diagnosed with CFS/ME using 13 
recognised criteria, or measure anxiety and depressive symptoms in the 20-30%[5, 6] of children 14 
that experience them. Three studies[50-52] were excluded from our review for these reasons. For 15 
example, studies evaluating Acceptance and Commitment Therapy[50] and Mindfulness-based 16 
therapies[51] show promising results in improving the physical health, symptom burden and 17 
‘emotional distress’ in children with functional somatic syndromes including CFS/ME but were 18 
excluded from this review because data for adolescent participants with CFS/ME were aggregated 19 
with those with other somatic syndromes, and the studies only measured general wellbeing 20 
outcomes rather than specifically validated anxiety and/or depression outcomes.  21 
 22 
There is a pressing need for more work in this area to identify efficacious treatments for anxiety and 23 





researchers to undertake paediatric CFS/ME interventions studies and use validated, diagnostic 1 
outcome measures of anxiety and depression.  2 
 3 
CONCLUSION 4 
This updated review highlights both the paucity of intervention studies in children with CFS/ME since 5 
1991 and the lack of forward movement in identifying effective treatments for paediatric CFS/ME 6 
and comorbid depression and anxiety over the last five years. The overall quality of the literature 7 
remains poor and calls for paediatric CFS/ME intervention studies to target anxiety and depression, 8 
measure outcomes with validated scales, or report outcomes in subsets of patients with clinical 9 
diagnoses of anxiety and depression, have not been met. Given that comorbid anxiety and 10 
depression in paediatric CFS/ME are associated with worse outcomes, unlikely to remit 11 
spontaneously without treatment, and can be incompatible with following standard CFS/ME 12 
treatment guidance, this needs to be addressed. Future research should: improve the quality of the 13 
literature by using validated scales (as well as analyse correlation between scales) and measure 14 
anxiety and/or depression as primary outcomes in large intervention studies of comorbid anxiety 15 
and/or depression in paediatric CFS/ME.  16 
 17 
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